Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Articles
Lung Cancer
,
Oncology
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
Wayne Kuznar
Read More
Leukemia
,
Oncology
Gilteritinib and CX-01 in the Treatment of Patients with Acute Myeloid Leukemia
Phoebe Starr
Read More
In the Literature
,
Oncology
Long-Term Outcomes Affect Cost-Effectiveness of CAR T-Cell Therapy for DLBCL
Read More
In the Literature
,
Oncology
Alpelisib Prolongs Progression-Free Survival in Advanced Breast Cancer with PIK3CA Mutation
Read More
In the Literature
,
Oncology
New Triple-Drug Regimen for Newly Diagnosed Patients with Multiple Myeloma
Read More
Leukemia
,
Oncology
Fixed-Duration Targeted Therapy with Venetoclax plus Obinutuzumab New Front-Line Standard for Patients with Chronic Lymphocytic Leukemia
Phoebe Starr
Read More
Biomarkers
,
Oncology
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
Read More
Cholangiocarcinoma
,
Oncology
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
Read More
FDA Approvals
Enfortumab Vedotin Promising Third-Line Option for Metastatic Urothelial Cancer
Phoebe Starr
Read More
FDA Approvals
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Read More
43
44
45
46
47
48
49
Page 46 of 244
Results 451 - 460 of 2434